Ribobio (苏州瑞博生物技术)

IPO

Advancing RNAi therapy for a new era of human health

Guangzhou, China · Founded 2004

Headquarters
Guangzhou
Employees
201–500
Founded
2004
Business Model
B2B
Last Round
Series E
Rounds
1

About

RiboBio (Suzhou Ribo Life Science Co., Ltd., HKEX: 06938.HK) is a clinical-stage biotechnology company focused on RNA interference (RNAi) technology and the development and commercialization of small nucleic acid drugs, founded in 2004 and headquartered in Guangzhou, China. The company has established a fully integrated small nucleic acid drug development platform covering the entire lifecycle from early research to commercialization, with therapeutic programs targeting cardiovascular, metabolic, renal, liver, and central nervous system diseases. RiboBio is Asia's largest oligonucleotide-based drug manufacturer and operates China's first cGMP-certified oligonucleotide API facility. The company maintains international R&D centers and has partnered with global pharmaceutical companies including Madrigal Pharmaceuticals on joint development programs.

Summary

Ribobio (苏州瑞博生物技术) is a Biotech company based in Guangzhou, China, founded in 2004.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to see all 2 rounds

IPO through Series E — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Ribobio (苏州瑞博生物技术) on Indexed.vc
<a href="https://indexed.vc/companies/ribobio"><img src="https://indexed.vc/api/badge/company/ribobio" alt="Ribobio (苏州瑞博生物技术) on Indexed.vc" width="260" height="76" /></a>